ClinicalTrials.gg
RecruitingNCT07681778RDH12Updated Oct 30, 2026

Safety and Tolerability of Subretinal OPGx-RDH12-1001 for LCA-Associated Inherited Retinal Degeneration (LCA-IRD)

A Phase 1/2 interventional study of OPGx-RDH12 in Leber Congenital Amaurosis and Leber Congenital Amaurosis (LCA), sponsored by Opus Genetics, Inc. Recruiting at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Opus Genetics, Inc · Phase 1/2, Interventional, and Treatment

How we know

Updated Oct 30, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Leber Congenital Amaurosis with a site in United States — 4 open to participants now, 9 under way, 3 of them phase 3. Leber Congenital Amaurosis · United States.

Planned enrollment
15th of 16
10 · median 18
Started
2026
the only one that year
Phase 1/2
9 of 23
1 open now
Registered
23rd of 23
by date

Among the 23 studies in Leber Congenital Amaurosis with a site in United States, this one is the 15th largest by planned enrollment of the 16 interventional ones that give a count, is the only one that started in 2026, is one of 9 in phase 1/2, and was the 23rd registered.

Leber Congenital Amaurosis

32 studies on the registry are indexed under Leber Congenital Amaurosis; 4 are open to participants now.

Browse Leber Congenital Amaurosis studies →

Open to participants now

4 of the 23 studies in Leber Congenital Amaurosis with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 4 Leber Congenital Amaurosis studies recruiting now, 4 set no upper age limit and none stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Leber Congenital Amaurosis with a site in United States, or all of them as a file.
02

Study summary

This study is an early-stage clinical trial (Phase 1b/2a) testing a gene therapy called OPGx-RDH12 for people with Leber Congenital Amaurosis (LCA) caused by mutations in the RDH12 gene, a rare genetic eye disease that leads to severe vision loss. The treatment is delivered as a one-time injection into the retina (subretinal space) of the worse-seeing eye, using a method similar to approved gene therapies like Luxturna. The study is designed to evaluate safety and effectiveness at two dose levels (1E11 and 3E11 viral genomes per eye) in small groups of 5 participants. Each group begins cautiously with 2 adults (age ≥18), treated at least one month apart, followed by FDA review before allowing adolescents (ages 12-17) to participate. An independent monitoring committee (IDMC) oversees safety throughout. After 3 adolescents are treated and followed for 3 months, the committee reviews all data to decide whether to move to a higher dose. However, if the lower dose (1E11 vg/eye) shows strong effectiveness in the first group, the study may expand by treating more adolescents at that same dose instead of increasing it further.

Read the detailed description

This is a Phase 1b/2a multicenter, open-label, and non-randomized dose-escalation safety study of up to two vector doses of OPGx-RDH12 administered via unilateral injection in participants with Leber Congenital Amaurosis (LCA) with autosomal-recessive retinol dehydrogenase 12 (RDH12) gene mutation(s). Administration will occur via a cannula into the subretinal space, using the standard technique for delivery of other adeno-associated virus (AAV) therapies including Luxturna®, the first United States Food and Drug Administration (FDA)-approved ocular gene therapy.

Up to 2 OPGx-RDH12 dose cohorts will be studied: 1E11 vg/eye (Cohort 1) and 3E11 vg/eye (Cohort 2). The treatment eye will be the eye with the worst visual function (as determined by visual acuity, full-field sensitivity testing [FST] and kinetic perimetry) or the non-dominant eye in cases of bilateral symmetric disease. Toxicity related to the administration of OPGx-RDH12 will be monitored in the eye using a comprehensive clinical monitoring plan and an Independent Data Monitoring Committee (IDMC).

Each cohort will enroll 5 participants. The first 2 participants will be adults (≥18 years old), treated at least 1 month apart. One month after the second participant's treatment, safety and efficacy data from the adult participants will be submitted to FDA for review and approval to open the study to adolescent participants (12-17 years old). The IDMC will next determine whether adolescent participants may be enrolled in the same dose cohort.

Three months after the third adolescent participant's treatment, the IDMC will review all safety and efficacy data from the cohort and determine whether to recommend escalation to the next dose cohort. Efficacy signals in Cohort 1 may justify conversion to a larger cohort of adolescent participants at the 1E11 vg/eye dose, with no further dose escalation.

03

Conditions studied

  • Leber Congenital Amaurosis
  • Leber Congenital Amaurosis (LCA)

Keywords

  • Gene therapy
  • IRD
  • LCA
  • Leber Congenital Amaurosis
  • OPGx-RDH12
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years (adult participants) or 12-17 years (adolescent participants) at the time of consent/assent.
  • Provide written and/or assent prior to any study procedures.
  • Willing to adhere to the clinical protocol and follow directions of the Investigator regarding post-surgery restrictions.
  • Are a good candidate for surgery, per the Investigator's judgment.
  • Have LCA with autosomal-recessive RDH12 mutation(s), confirmed by a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory. Historic testing, up to 15 years prior to date of consent, may be considered.
  • Clinical diagnosis of LCA with RDH12 mutation(s), in the judgment of the Investigator.
  • BCVA 20/200 (1.0 logarithm of the minimum angle of resolution [logMAR]) or worse for the sentinel adult in each cohort; BCVA 20/40 (0.5 logMAR) or worse for all subsequent participants in each cohort.

Exclusion criteria

Exclusion Criteria:

  • Women of (WOCBP) who are pregnant, lactating, and/or unwilling to use effective from Screening through 1 year after IMP administration.
  • Men who are unwilling to use effective contraception from Screening through 180 days after IMP administration.
  • Have an ocular infection, a pre-existing eye condition, or a complicating systemic disease that could preclude the planned surgery or any future ocular surgery. This includes individuals who are and/or on continuous systemic immunosuppressive therapy.
  • Have a past or current condition that may preclude participation in the study, interfere with outcome measure testing or test results, or otherwise make the potential participant unsuitable for the study.
  • Have previously received gene therapy of any kind.
  • In either eye, have undergone intraocular surgery within 90 days prior to planned IMP administration or have active inflammation at Screening resulting from prior ocular surgery.
  • Have used any device or investigational drug within 90 days (or 5 half-lives of the drug, whichever is longer) prior to planned IMP administration or intend to participate in another drug or device study during the same period as the current study.
  • Have received or plan to receive a vaccination within 6 weeks prior to or 6 weeks after IMP administration. Note: For the influenza vaccine, the exclusionary period is shorter: 2 weeks prior to and 5 weeks after IMP administration (i.e., during treatment).
  • Have received anticoagulant therapy within 2 weeks prior to planned IMP administration.
  • Currently use medications that are potentially neuroprotective/beneficial or retinotoxic.
  • Are incapable of performing visual function testing (e.g., FST), with or without assistance, for reason other than poor vision.
  • Have any to a course of oral steroids, in the opinion of the Investigator.
  • Have a known history of to constituents or in the pharmaceutical formulation of the IMP.
  • Have a known or active infection of (HIV) or or C virus.
  • Have a known or active infection of herpes simplex virus with ocular manifestations.
  • Are an employee of the Sponsor or a relative of the Investigator or investigative site staff.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    OPGx-RDH12

    Administration of OPGx-RDH12 will occur via a cannula into the subretinal space, using the standard technique for delivery of other adeno-associated virus (AAV) therapies including Luxturna®. A dose of 1E11 vg/eye will be injected sub-retinally one time into the treatment eye. The treatment eye will be the eye with the worst visual function (as determined by visual acuity, full-field sensitivity testing \[FST\] and kinetic perimetry) or the non-dominant eye in cases of bilateral symmetric disease.

    Drug: OPGx-RDH12

Interventions

  • DrugOPGx-RDH12

    Experimental gene therapy

06

What researchers measure

Primary outcomes

  1. Number of dose-limiting toxicity (DLT) events at the proposed doses

    Time frame: 5 Years

  2. Number and severity of procedure-related AEs

    Time frame: 5 Years

  3. Number and severity of AEs related to OPGx-RDH12

    Time frame: 5 Years

  4. Qualitative assessment of cross-sectional spectral-domain optical coherence tomography (SD-OCT), fundus photography, and fundus autofluorescence (FAF) images

    Time frame: 5 Years

Secondary outcomes

  1. Change from baseline best corrected visual acuity (BCVA) with manifest refraction

    Time frame: 5 Years

  2. Change from baseline Low luminance visual acuity (LLVA)

    Time frame: 5 Years

  3. Change from baseline Kinetic visual fields

    Time frame: 5 Years

  4. Change in baseline Microperimetry

    Time frame: 5 Years

  5. Change from baseline Light- and dark-adapted full-field sensitivity testing (FST)

    Time frame: 5 Years

  6. Change in baseline Pupillometry

    Time frame: 5 Years

  7. Change from baseline Multi-Luminance Orientation and Mobility Test (MLoMT)

    Time frame: 5 Years

  8. Change from baseline Participant-reported outcomes (Michigan Retinal Degeneration Questionnaire [MRDQ])

    The Michigan Retinal Degeneration Questionnaire (MRDQ) measures functional vision disability across 7 visual domains (e.g., central vision, color vision, contrast sensitivity). Rather than a simple sum, it uses an item-response theory (IRT) model, resulting in person-ability/disability scores (θ) ranging from -3 to +3. -3: Represents the lowest experienced disability (least difficulty or best visual function). +3: Represents the highest experienced disability (most severe difficulty or worst visual function).

    Time frame: 5 Years

  9. Change from baseline Participant-reported outcomes (Patient Global Impressions of Severity [PGI-S])

    The Patient Global Impression of Severity \[PGI-S\] is a standardized, single-item questionnaire that allows patients to subjectively rate how severe their medical condition feels at a given moment. The Patient Global Impression of Severity \[PGI-S\] 5-point scale ranges from a minimum of 0 (None) to a maximum of 4 (Very severe).

    Time frame: 5 Years

  10. Change from Baseline Participant-reported Outcomes (Patient Global Impressions of Change [PGI-C])

    The Patient Global Impressions of Change (PGIC) is a widely used patient-reported outcome (PRO) questionnaire in clinical trials. It evaluates how a patient's overall health, functioning, or symptoms have changed following a treatment compared to their baseline. A 7-point scale is utilized for the Patient Global Impression of Change (PGI-C), the minimum value is 1 (very much improved) and the maximum value is 7 (very much worse).

    Time frame: 5 Years

  11. Change from Baseline Participant-reported outcomes (Patient Global Impressions of Improvement [PGI-I])

    The Patient Global Impression of Improvement (PGI-I) is a standardized, single-item patient-reported outcome (PRO) scale used in clinical trials. It asks participants to rate the change in their overall health or specific condition since beginning a therapy, treatment, or surgery. Patients rate their perceived change on a balanced 7-point scale ranging from 1 to 7: 1 = very much better, 7 = very much worse.

    Time frame: 5 Years

07

Study locations

1 of 4 sites recruiting
  • Associated Retina Consultants
    Phoenix, Arizona 85020, United States
    Not yet recruiting
  • Perelman School of Medicine, University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
    Not yet recruiting
    • Tomas Aleman, MD · Principal investigator
  • Retina Foundation of the Southwest
    Dallas, Texas 75231, United States
    Not yet recruiting
    • Mark Pennesi, MD, Ph.D. · Principal investigator
  • Retina Consultants of Texas & Retina Group Inc.
    Houston, Texas 77401, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Oct 2026; primary completion for Dec 2032, 74 months later.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, on Oct 30, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2026
First posted
Jul 2, 2026
StartEst.
Oct 2026was Sep 2026
Primary completionEst.
Dec 2032
CompletionEst.
Jul 2034
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 30, 2026
Sites
1 site added. 4 sites changed recruiting status (3 now not yet recruiting, 1 now recruiting)
Show 4 sites
  • Associated Retina Consultants · Phoenix, United Statesno status→Not yet recruiting
  • Perelman School of Medicine, University of Pennsylvania · Philadelphia, United Statesno status→Not yet recruiting
  • Retina Foundation of the Southwest · Dallas, United Statesno status→Not yet recruiting
  • Retina Consultants of Texas & Retina Group Inc. · Houston, United Statesno status→Recruiting
Show site
  • Retina Foundation of the Southwest · Dallas, United States
across 2 updates, Oct 23, 2026 – Oct 30, 2026
Start date
Sep 2026→Oct 2026
Oct 30, 2026
Site contacts
Changed at 3 sites. See the sites
Show 3 sites
  • Associated Retina Consultants · Phoenix, United StatesContact none listed→•••5458Contact added k•••@doctrials.com · •••5458
  • Retina Foundation of the Southwest · Dallas, United StatesContact removed r•••@retinaconsultantstexas.com · •••5921
  • Retina Consultants of Texas & Retina Group Inc. · Houston, United StatesContact added r•••@retinaconsultantstexas.com · •••5921
Oct 30, 2026
Show all 2 updates
  1. Oct 30, 2026
    Not yet recruiting→Recruiting
    4 sites changed recruiting status (3 now not yet recruiting, 1 now recruiting)
    Show 4 sites
    • Associated Retina Consultants · Phoenix, United Statesno status→Not yet recruiting
    • Perelman School of Medicine, University of Pennsylvania · Philadelphia, United Statesno status→Not yet recruiting
    • Retina Foundation of the Southwest · Dallas, United Statesno status→Not yet recruiting
    • Retina Consultants of Texas & Retina Group Inc. · Houston, United Statesno status→Recruiting
    Start date Sep 2026→Oct 2026
    Site contacts Changed at 3 sites. See the sites
    Show 3 sites
    • Associated Retina Consultants · Phoenix, United StatesContact none listed→•••5458Contact added k•••@doctrials.com · •••5458
    • Retina Foundation of the Southwest · Dallas, United StatesContact removed r•••@retinaconsultantstexas.com · •••5921
    • Retina Consultants of Texas & Retina Group Inc. · Houston, United StatesContact added r•••@retinaconsultantstexas.com · •••5921
    + 2 other changes: verification date and description
  2. Oct 23, 2026
    1 site added
    Show site
    • Retina Foundation of the Southwest · Dallas, United States
    + 1 other change: date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07681778
Lead sponsor
Opus Genetics, Inc
Responsible party
Sponsor
First posted
Jul 2, 2026
Start date
Oct 2026 (estimated)
Primary completion
Dec 2032 (estimated)
Completion
Jul 2034 (estimated)
Last update
Oct 30, 2026

Study contacts

Study Director
Contact
ct.gov_inquiries@opusgtx.com
984-884-6030

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion